Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
Know Labs, Inc., now reflected in SEC filings as USBC, Inc., reports developments tied to its completed control transaction, digital-asset treasury strategy and continuing diagnostic-technology work. Recent updates include the company's shift toward the USBC token, a digital U.S. dollar product using blockchain and digital identity, alongside governance, shareholder voting and capital-structure actions.
The company's legacy research division continues work on Radio Frequency Dielectric Spectroscopy (RFDS), a spectroscopy platform designed to capture molecular signatures in wearable, mobile or bench-top formats. News also covers non-invasive analyte monitoring, pH detection research, a planned non-invasive glucose-monitor application requiring FDA clearance, licensing activity through Know Labs Technology Licensing and public-company status changes.
Know Labs, Inc. (KNW) has successfully completed its underwritten public offering, closing on 4,140,000 shares of Common Stock at $2.00 per share, generating approximately $8.28 million in gross proceeds. The offering included the underwriter’s option for an additional 540,000 shares. Trading for KNW stock commenced on the NYSE American on September 16, 2022. Boustead Securities, LLC served as the sole underwriter for the transaction.
Know Labs, Inc. (NYSE American: KNW) has announced a public offering of 3,600,000 shares at $2.00 per share, aiming to raise approximately $7.2 million before discounts and expenses. The offering is set to close on or around September 20, 2022, following a trading debut on September 16, 2022. Boustead Securities, LLC is acting as the sole underwriter. The company’s advanced Bio-RFID technology aims to revolutionize non-invasive medical diagnostics, starting with a glucose monitoring product pending FDA clearance.